References
- Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev. Vaccines10(5), 617–634 (2011).
- Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev. Vaccines10(5), 575–588 (2011).
- Blanchard-Rohner G, Pollard AJ. Long-term protection after immunization with protein–polysaccharide conjugate vaccines in infancy. Expert Rev. Vaccines10(5), 673–684 (2011).
- Heath PT. An update on vaccination against group B streptococcus. Expert Rev. Vaccines10(5), 685–694 (2011).
- Verdijk P, Rots NY, Bakker WAM. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev. Vaccines10(5), 635–644 (2011).
- Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev. Vaccines10(5), 695–708 (2011).
- Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev. Vaccines10(5), 589–599 (2011).
- Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev. Vaccines10(5), 659–672 (2011).
- Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines10(5), 645–658 (2011).
- Kitchin NRE. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Expert Rev. Vaccines10(5), 605–615 (2011).